This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Review

. 2001 Jul;52(1):107-17.

doi: 10.1046/j.0306-5251.2001.temp.1441.x.

Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential--towards a consensus

G T Tucker¹, J B Houston, S M Huang

Affiliations

Affiliation

¹ Molecular Pharmacology & Pharmacogenetics, Division of Clinical Sciences, University of Sheffield, The Royal Hallamshire Hospital, Sheffield S10 2JF, UK. G.T.Tucker@sheffield.ac.uk

PMID: 11453898
PMCID: PMC2014497
DOI: 10.1046/j.0306-5251.2001.temp.1441.x

Review

Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential--towards a consensus

G T Tucker et al. Br J Clin Pharmacol. 2001 Jul.

. 2001 Jul;52(1):107-17.

doi: 10.1046/j.0306-5251.2001.temp.1441.x.

Authors

G T Tucker¹, J B Houston, S M Huang

Affiliation

¹ Molecular Pharmacology & Pharmacogenetics, Division of Clinical Sciences, University of Sheffield, The Royal Hallamshire Hospital, Sheffield S10 2JF, UK. G.T.Tucker@sheffield.ac.uk

PMID: 11453898
PMCID: PMC2014497
DOI: 10.1046/j.0306-5251.2001.temp.1441.x

No abstract available

PubMed Disclaimer

Figures

Figure 1
Impact of [I]/K_i on the ratio of the AUC of substrate ([S] < K_m) in the presence and absence of a competitive inhibitor.

Figure 2
An algorithm for evaluating drug–drug interactions.

See this image and copyright information in PMC

Similar articles

EUFEPS conference report. Optimising drug development: strategies to assess drug metabolism/transporter interaction potential - towards a consensus. European Federation of Pharmaceutical Sciences.
Tucker GT, Houston JB, Huang SM. Tucker GT, et al. Eur J Pharm Sci. 2001 Jul;13(4):417-28. doi: 10.1016/s0928-0987(01)00148-8. Eur J Pharm Sci. 2001. PMID: 11480400 No abstract available.
Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential--toward a consensus.
Tucker GT, Houston JB, Huang SM. Tucker GT, et al. Pharm Res. 2001 Aug;18(8):1071-80. doi: 10.1023/a:1010994022294. Pharm Res. 2001. PMID: 11587475 Review. No abstract available.
[Transporter-mediated drug-drug interaction in renal and hepatic elimination processes].
Nagai J. Nagai J. Nihon Yakurigaku Zasshi. 2010 Jan;135(1):34-7. doi: 10.1254/fpj.135.34. Nihon Yakurigaku Zasshi. 2010. PMID: 20075569 Review. Japanese. No abstract available.
Prediction of drug metabolism and interactions on the basis of in vitro investigations.
Pelkonen O, Turpeinen M, Uusitalo J, Rautio A, Raunio H. Pelkonen O, et al. Basic Clin Pharmacol Toxicol. 2005 Mar;96(3):167-75. doi: 10.1111/j.1742-7843.2005.pto960305.x. Basic Clin Pharmacol Toxicol. 2005. PMID: 15733211 Review.
Molecular mechanisms of drug metabolism in the critically ill.
Park GR. Park GR. Br J Anaesth. 1996 Jul;77(1):32-49. doi: 10.1093/bja/77.1.32. Br J Anaesth. 1996. PMID: 8703629 Review. No abstract available.

See all similar articles

Cited by

Prediction of in vivo drug-drug interactions from in vitro data: impact of incorporating parallel pathways of drug elimination and inhibitor absorption rate constant.
Brown HS, Ito K, Galetin A, Houston JB. Brown HS, et al. Br J Clin Pharmacol. 2005 Nov;60(5):508-18. doi: 10.1111/j.1365-2125.2005.02483.x. Br J Clin Pharmacol. 2005. PMID: 16236041 Free PMC article.
Assessment of compound hepatotoxicity using human plateable cryopreserved hepatocytes in a 1536-well-plate format.
Moeller TA, Shukla SJ, Xia M. Moeller TA, et al. Assay Drug Dev Technol. 2012 Feb;10(1):78-87. doi: 10.1089/adt.2010.0365. Epub 2011 Nov 4. Assay Drug Dev Technol. 2012. PMID: 22053711 Free PMC article.
Integration of preclinical and clinical data with pharmacokinetic modeling and simulation to evaluate fexofenadine as a probe for hepatobiliary transport function.
Swift B, Tian X, Brouwer KL. Swift B, et al. Pharm Res. 2009 Aug;26(8):1942-51. doi: 10.1007/s11095-009-9909-z. Epub 2009 Jun 4. Pharm Res. 2009. PMID: 19495943 Free PMC article.
Predictions of the in vivo clearance of drugs from rate of loss using human liver microsomes for phase I and phase II biotransformations.
Mohutsky MA, Chien JY, Ring BJ, Wrighton SA. Mohutsky MA, et al. Pharm Res. 2006 Apr;23(4):654-62. doi: 10.1007/s11095-006-9663-4. Epub 2006 Mar 24. Pharm Res. 2006. PMID: 16550474
Primary Hepatocytes Cultured on a Fiber-Embedded PDMS Chip to Study Drug Metabolism.
Liu Y, Hu K, Wang Y. Liu Y, et al. Polymers (Basel). 2017 Jun 10;9(6):215. doi: 10.3390/polym9060215. Polymers (Basel). 2017. PMID: 30970894 Free PMC article.

See all "Cited by" articles

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
Other Literature Sources
- The Lens - Patent Citations Database
Medical
- MedlinePlus Health Information